India Panel Urges Considering Aggressive Marketing As “Irrational Use”
This article was originally published in PharmAsia News
Executive Summary
An Indian steering committee said any drug maker’s aggressive marketing should be considered irrational use subject to penalties, and it called for a permanent rule to bind the industry to ethical-behavior standards.